The incidence of recurrence and hypothyroidism after radioiodine treatment in patients with hyperthyroidism in Trakya, a mild iodine deficiency area, during the period 1991-2003

Annals of Nuclear Medicine

Volumn 19, Issue 8, 2005, Pages 737-742

  Ustun, Funda ^a   Yuksel, Mahmut ^a   Durmus Altun, Gülay ^a   Kaya, Meryem ^a   Çermik, Tevfik Fikret ^a   Sarikaya, Ali ^a   Berkarda, Sakir ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Graves' disease; Iodine deficiency; Radioiodine therapy; Toxic adenoma; Toxic multinodular goiter

Indexed keywords

RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COURSE EVALUATION; DISEASE DURATION; DOSE CALCULATION; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOXIC GOITER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; GOITER; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PREVALENCE; RADIOPHARMACEUTICALS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TURKEY;

EID: 31744449996     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF02985126     Document Type: Article

References (32)

1. Cooper DS. Treatment of thyrotoxicosis. In: The Thyroid, A Fundamental and Clinical Text. Braverman LE, Utiger RD (eds), Philadelphia, New York; Lippincott-Raven, 1996: 713-734.
2. Delange F. Iodine deficiency in Europe and its consequence: an update. Eur J Nucl Med 2002; 29 (Suppl): S404-416.
3. Urgancioglu I, Hatemi H, Yenici O, Uslu I, Kaya H, Benli M, et al. Endemic goitre screening in Turkey. In: Endemic goitre in Turkey (in Turkish), Urgancioglu I, Hatemi H (eds), Istanbul; Emek Matb, 1989: 9-41.
4. Yordam N, Ozon A, Alikasifoglu A, Ozgen A, Ceren N, Zafer Y, et al. Iodine deficiency in Turkey. Eur J Pediatr 1999; 158: 501-505.
5. Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999; 84: 561-566.
6. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med 2002; 29: S471-478.
7. Rivkees SA, Sklar C, Freemark M. The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998; 83: 3767-3776.
8. Burgi H, Kohler M, Morselli B. Thyrotoxicosis incidence in Switzerland and benefit of improved iodine supply. The Lancet 1998; 352: 1034.
9. Kita T, Yokoyama K, Kinuya S, Taki J, Michigishi T, Tonami N. Single dose planning for radioiodine-131 therapy of Graves' disease. Ann Nucl Med 2004; 18: 151-155.
10. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86: 3611-3617.
11. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991; 34: 71-76.
12. Berglund J, Christensen SB, Dymling JF, Hallengren B. The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmo during the period 1970-1974. J Intern Med 1991; 229: 435-442.
13. Berkarda S, Berkarda S, Okay S, Demirezen O, Güray M. Thyroid screening in Üyüktatar Town of Edirne. In: Cerrahpaşa Medical Faculty Endemic Goitre Screening (TT-55/80), (in Turkish) Hatemi H, Urgancioglu I (eds), Istanbul; Emek Matb, 1986: 13.
14. Erdogan G, Erdogan MF, Emral R, Bastemir M, Sav H Haznedaroglu D, et al. Iodine status and goitre prevalence in Turkey before mandatory iodization. J Endocrinol Invest 2002; 25: 224-228.
15. Reiners C. Radioiodine treatment of Basedow's disease: interference and influence factors, risk estimation. Exp Clin Endocrinol 1991; 97: 275-285.
16. 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002; 87: 1073-1077.
17. Leary AC, Grealy G, Higgins TM, Buckley N, Barry DG, Murphy D, et al. Long-term outcomes of treatment of hyperthyroidism in Ireland. Ir J Med Sci 1999; 168: 47-52.
18. Staffurth JS. Hypothyroidism following radioiodine treatment of thyrotoxicosis. J R Coll Physicians Lond 1987; 21: 55-57.
19. Reinwein D, Benker G, Konig MP, Pinchera A, Schatz H, Schleusener A. The different type of hyperthyroidism in Europe. Results of a prospective survey of 924 patients. J Endocrinol Invest 1988; 11: 193-200.
20. Belfiore A, Sava L, Runello F, Tomaselli L, Vigneri R. Solitary autonomously functioning thyroid nodules and iodine deficiency. J Clin Endocrinol Metab 1983; 56: 283-287.
21. Huysmans DA, Hermus AR, Corstens FH, Kloppenborg PW. Long-term results of two schedules of radioiodine treatment for toxic multinodular goitre. Eur J Nucl Med 1993; 20: 1056-1062.
22. Kinser JA, Roesler H, Furrer T, Grutter D, Zimmermann H. Nonimmunogenic hyperthyroidism: Cumulative hypothyroidism incidence after radioiodine and surgical treatment. J Nucl Med 1989; 30: 1960-1965.
23. Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, et al. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes 1999; 107: 70-74.
24. Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med 1996; 37: 228-232.
25. Erickson D, Gharib H, Li H, van Heerden JA. Treatment of patients with toxic multinodular goitre. Thyroid 1998; 8: 277-282.
26. Freitas JE. Therapeutic options in the management of toxic and nontoxic nodular goitre. Semin Nucl Med 2000; 30: 88-97.
27. Mishra A, Agarwal A, Agarwal G, Mishra SK. Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg 2001; 25: 307-310.
28. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 2002: 29: 1118-1124.
29. Huszno B, Hubalewska-Hola A, Baldys-Waligorska A, Sowa-Staszczak A, Szybinski Z. The impact of iodine prophylaxis on thyroid 131-iodine uptake in the region of Krakow, Poland. J Endocrinol Invest 2003; 26: 7-10.
30. Mishra A, Mishra SK, Agarwal A, Das BK, Agarwal G, Gambhir S. Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area. World J Surg 2002; 26: 153-157.
31. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 685-687.
32. Laurberg P, Nohr SB, Pedersen KM, Hreidarsson AB, Andersen S, Bulow Pedersen I, et al. Thyroid disorders in mild iodine deficiency. Thyroid 2000; 10: 951-963.